Latest Paclitaxel Stories
CAMBRIDGE, Mass., Oct. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel (Taxol®) in the neoadjuvant setting of HER2-negative breast cancer patients. (Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO ) The Phase 2 study is designed to evaluate whether the combination of MM-121 with...
A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy. The researchers published their findings, "Cannabidiol Prevents the Development of Cold and Mechanical Allodynia in Paclitaxel-Treated Female C57Bl6 Mice," in the journal Anesthesia and Analgesia. The researchers developed animal models and tested the ability of...
Results lead to Scottsdale oncologists heading a large phase III study being conducted worldwide Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new drug combination consisting of a standard drug called gemcitabine and a drug called nab-paclitaxel for patients with advanced pancreatic cancer. The results of this...
NATICK, Mass., Oct. 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has started patient enrollment in the OMEGA clinical trial, designed to evaluate the safety and effectiveness of the Company's OMEGA(TM) Platinum Chromium Bare-Metal Coronary Stent System in treating patients with a single coronary artery lesion. This prospective, single-arm trial will enroll 328 patients at 40 sites in the U.S. and Europe. The first patient was enrolled this week by Prof. Andrejs...
Results lead to Scottsdale oncologists heading a large Phase III study being conducted worldwide SCOTTSDALE, Ariz., Oct. 4, 2011 /PRNewswire-USNewswire/ -- Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new drug combination consisting of a standard drug called gemcitabine and a drug called nab-paclitaxel for patients...
A common chemotherapy drug has been successfully delivered to cancer cells inside tiny microparticles using a method inspired by our knowledge of how the human immune system works. The drug, delivered in this way, reduced ovarian cancer tumours in an animal model by 65 times more than using the standard method. This approach is now being developed for clinical use. The research was funded by, among others, the Biotechnology and Biological Sciences Research Council (BBSRC) Follow-on Fund -...
Results from the Bern-Rotterdam cohort study Results of the independently-funded Bern-Rotterdam cohort study provide robust evidence of an "important" reduction in overall and very late stent thrombosis. The reduction in incidence was found when a newer generation everolimus-eluting stent (EES) was compared with early generation drug-eluting stents (DES) at long-term follow-up. "The near elimination of stent thrombosis observed between one and four years after implantation shows that...
SEATTLE, Aug. 18, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC and MTA: CTIC) announced that enrollment has opened for a randomized phase II clinical study comparing the combination of OPAXIO (paclitaxel poliglumex, PPX) and radiation ("RT") to the combination of temozolomide ("TMZ") and RT for patients with newly diagnosed glioblastoma, a high-grade malignant brain tumor. The objectives of the study are to determine if OPAXIO and RT improve progression free survival...
HONG KONG, Aug. 16, 2011 /PRNewswire/ -- OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte(TM) paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis. The two-year follow-up data from the prospective, randomized TRIAS pilot study were published in Catheterization and Cardiovascular Interventions. No...
CALGARY, Aug. 2, 2011 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that an international team of researchers has reported on a study in the online version of Molecular Therapy, a publication of The American Society of Gene and Cell Therapy, investigating the timing of chemotherapy delivery that optimizes the efficacy of systemic REOLYSIN(®). The paper is entitled "Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for...
